The LIPID Study
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study:
the LIPID Study was a randomised, double-blind, placebo-controlled parallel group study conducted in 9,014 patients recruited from 87 centres in Australia and New Zealand (39). It was designed to examine the effects of 40mg pravastatin o.d on cardiovascular outcomes in patients who were stable after myocardial infarction or hospitalisation for unstable angina 3-36 months previously. Patients had baseline total cholesterol of 4.0-7.0mmol/L and triglycerides <5mmol/L and at baseline a high percentage received other evidence-based therapies for coronary heart disease. Over a mean follow-up of 6.0 years there was a highly significant reduction in coronary heart disease mortality, the primary study endpoint, total mortality and all other prespecified cardiovascular end-points.